Profusa

Profusa is a digital health company developing injectable biosensor hydrogel technology for continuous, real-time biochemical monitoring of tissue oxygen and other analytes in vivo. Its lead product, the Lumee Oxygen platform, is CE Marked in Europe and is being evaluated in clinical and commercial programs for peripheral artery disease, critical limb ischemia, and other vascular conditions. The company implemented its third reverse split of 2026 — a 1-for-4 split effective August 18, 2026 — after a 1-for-25 split effective July 7, 2026, both to maintain Nasdaq listing compliance, and in August 2026 signed a non-binding option term sheet to acquire a privately held diagnostics and toxicology testing business.